Results 141 to 150 of about 68,425 (202)

Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle‐Aged but Not Older Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Low serum testosterone concentration has been reported to be causally linked to the risk of Type 2 diabetes (T2D). The benefit of T2D protection has been demonstrated to continue up to serum testosterone concentrations of 461 ng/dL (16 nmol/L).
Mahesh M. Umapathysivam   +5 more
wiley   +1 more source

Unveiling the BMI Risk Threshold for Osteoarthritis: Multi‐Database Causal and Nonlinear Evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To characterize the nonlinear relationship between BMI and osteoarthritis (OA), and to identify BMI thresholds that inform precise prevention strategies. Methods This multi‐database study integrated Global burden of disease 2021, National Health and Nutrition Examination Survey 2007–2018, and Genome‐Wide Association Studies.
Shaohong Yu   +9 more
wiley   +1 more source

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin   +6 more
wiley   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey   +4 more
wiley   +1 more source

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m2 and at least one obesity‐related complication) or obesity (BMI ≥ 30 kg/m2), without diabetes, using data ...
Wojciech Michalak   +7 more
wiley   +1 more source

Cost‐Effectiveness of NT‐proBNP–Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real‐World Evidence From the Hong Kong Diabetes Biobank

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Heart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost‐effectiveness of NT‐proBNP‐guided cardiovascular risk stratification to guide cardioprotective treatment. Materials and Methods We developed a four‐
Abby Q. Y. Li   +6 more
wiley   +1 more source

A J-shaped association between weight-adjusted waist index and cardiovascular disease: a longitudinal study from the CHARLS database. [PDF]

open access: yesBMC Public Health
Wang J   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy